Cost Considerations Drive Lean Technology in Biomanufacturing

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-05-15-2017
Volume 2017 eBook
Issue 1
Pages: s4-s7

Manufacturing for originator molecules is restricted by regulations, but drug makers can exploit newer technologies for the manufacture of biosimilars.

The approval of biosimilars for the US market has created a need for more efficient manufacturing processes.

Manufacturers are developing processes for cost efficiency and reliability using newer technology to compete with innovator products manufactured with legacy processes.

Innovations include more productive cell lines, single-use systems, and powerful analytical methods.

Download

Pharmaceutical Technology’s 2017 Biologics and Sterile Drug Manufacturing eBook

.

 

Articles in this issue
SGS-Article_225.jpg
Clean, Disinfect, and Validate
Bioburden_225-1.jpg
Kill the Bioburden, Not the Biological Indicator
Cryoport_225.jpg
Cold Chain Logistics for Personalized Medicine: Dealing With Complexity
RawMaterials_225.jpg
Ensuring the Biological Integrity of Raw Materials
TechTransfer_225.jpg
Getting Biopharmaceutical Tech Transfer Right the First Time
Vetter_225.jpg
Developing an Injectable Compound for a Dual- Chamber Delivery System
GSK_225.jpg
Case Study: Retrofitting Two New High-Purity Water Systems
SUBioreactors_225.jpg
Single-Use Bioreactors Have Reached the Big Time
ParallelProcessing_225.jpg
Parallel Processing
Biosims_225.jpg
Cost Considerations Drive Lean Technology in Biomanufacturing
Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Related Content
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

FDA CBER Director Peter Marks Resigns

Susan Haigney
March 31st 2025
Article

Marks called out an ‘assault’ on truth and science in his resignation letter, which has sent the bio/pharmaceutical industry reeling.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

EMA Recommends Five New Medicines for Approval

Patrick Lavery
March 28th 2025
Article

Three of the five are biosimilars, and seven additional medicines received recommendations for indication extensions.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA Issues Warning Letter to Aspen Biopharma Labs for API Manufacturing Deviations

Feliza Mirasol
March 27th 2025
Article

In the latest of a series of warning letters to India-based API manufacturers, FDA issued a warning letter to Aspen for deviations in CGMP in the production of APIs.

TOP NEWS on grunge world map | Image Credit: © Sean K - stock.adobe.com

BIO Survey: Tariffs May Reduce Access, Delay Innovation, Create Red Tape

Patrick Lavery
March 27th 2025
Article

The Biotechnology Innovation Organization’s new membership survey said that 90% of US biotech companies rely on imported components for at least half of their FDA-approved products.